Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IGF2R | P11717 | 2/20 | 0.40 |
| ▸ | LGALS3 | P17931 | 1/20 | 0.37 |
| ▸ | SELL | P14151 | 3/20 | 0.36 |
| ▸ | SELP | P16109 | 3/20 | 0.36 |
| ▸ | SELE | P16581 | 3/20 | 0.36 |
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
| ▸ | G6PD | P11413 | 1/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.36 |
| ▸ | RAD52 | P43351 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17918994 | 0.83 | FOLH1 (0.43) | IGF2RLGALS3SELLSELPSELE | |
| SCHEMBL32684423 | 0.79 | IGF2R (0.41) | IGF2RLGALS3SELLSELPSELE | |
| Cellobiose SCHEMBL8673451 | 0.79 | IGF2R (0.47) | IGF2RLGALS3LMNAALOX15RAD52 | |
| SCHEMBL8673458 | 0.79 | IGF2R (0.46) | IGF2RLGALS3LMNAALOX15RAD52 | |
| SCHEMBL4435763 | 0.77 | G6PD (0.36) | IGF2RLGALS3G6PD | |
| SCHEMBL2303130 | 0.75 | PYGB (0.33) | IGF2RLGALS3 | |
| SCHEMBL2723573 | 0.73 | PYGB (0.43) | — | |
| SCHEMBL14667222 | 0.72 | L3MBTL1 (0.42) | SELLSELPSELE | |
| SCHEMBL14667225 | 0.72 | L3MBTL1 (0.42) | SELLSELPSELE | |
| SCHEMBL28444663 | 0.72 | CA12 (0.44) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 399 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240269274-A1 | TREATMENT FOR BONE DISEASES | UCB PHARMA S.A. (BE) | 2024-08-15 | — | — | US | claimed |
| US-20210060160-A1 | TREATMENT FOR BONE DISEASES | UCB PHARMA, S.A. (BE) | 2021-03-04 | — | — | US | claimed |
| EP-3626267-A1 | TREATMENT FOR BONE DISEASES | UCB Pharma, S.A. (BE) | 2020-03-25 | — | — | EP | claimed |
| US-20180169235-A1 | TREATMENT FOR BONE DISEASES | UCB PHARMA, S.A. (BE) | 2018-06-21 | — | — | US | claimed |
| US-9925260-B2 | Treatment for bone diseases | UCB PHARMA S.A. (GB) | 2018-03-27 | — | — | US | claimed |
| EP-2869844-A1 | TREATMENT FOR BONE DISEASES | UCB Pharma S.A. (BE) | 2015-05-13 | — | — | EP | claimed |
| CN-104619342-A | Treatment of bone disorders | UCB PHARMA SA | 2015-05-13 | — | — | CN | claimed |
| US-20140030268-A1 | TREATMENT FOR BONE DISEASES | UCB PHARMA S.A. (GB) | 2014-01-30 | — | — | US | claimed |
| WO-2014006100-A1 | TREATMENT FOR BONE DISEASES | UCB PHARMA S.A. (BE) | 2014-01-09 | — | — | WO | claimed |
| EP-2349326-A2 | A NEW PHARMACEUTICAL PRODUCT | Oulun Yliopisto (FI) | 2011-08-03 | — | — | EP | claimed |
| US-20100124548-A1 | Pharmaceutical product | UNIVERSITY OF OULU (FI) | 2010-05-20 | — | — | US | claimed |
| WO-2010049590-A2 | A NEW PHARMACEUTICAL PRODUCT | OULUN YLIOPISTO (FI) | 2010-05-06 | — | — | WO | claimed |
| US-12622946-B2 | HLA-DR/CII peptide complexes for treating arthritis | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. (DE) | 2026-05-12 | — | — | US | disclosed |
| EP-4725548-A2 | C-TERMINAL ANTIBODY VARIANTS | AMGEN, INC. (US) | 2026-04-15 | — | — | EP | disclosed |
| US-12570734-B2 | C-terminal anti-sclerostin antibody variants | AMGEN INC. (US) | 2026-03-10 | — | — | US | disclosed |
| EP-3774879-B1 | C-TERMINAL ANTIBODY VARIANTS | AMGEN INC (US) | 2026-01-28 | — | — | EP | disclosed |
| US-5589346-A | Method of monitoring markers of bone metabolism | BIOQUANT, INC. (US) | 1996-12-31 | — | — | US | disclosed |
| WO-1995035504-A1 | METHOD OF MONITORING MARKERS OF BONE METABOLISM | BIOQUANT, INC. (US) | 1995-12-28 | — | — | WO | disclosed |
| EP-0675903-A1 | BONE RESORPTION ASSAY | Baylink, David J (US) | 1995-10-11 | — | — | EP | disclosed |
| WO-1994014844-A1 | BONE RESORPTION ASSAY | BAYLINK DAVID J (US) | 1994-07-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12570734-B2 | C-terminal anti-sclerostin antibody variants | SOST, VSIG8, SET | IGF2R 2326/4885LGALS3 2942/4885SELL 145/4885 |
| US-12622946-B2 | HLA-DR/CII peptide complexes for treating arthritis | HLA-DRB1, MICA, CD74 | IGF2R 2302/4885LGALS3 2373/4885SELL 996/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.